Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Aspirin / butalbital / caffeine / codeine price, strengths & recalls

Generic of Ascomp

Pharmacies pay $30.85 for 30 capsules of Aspirin / butalbital / caffeine / codeine 325 mg / 50 mg / 40 mg / 30 mg capsule this week. 2 manufacturers make it. Its official label last changed on May 28, 2026.

Generic
Pharmacies pay$30.85for 30 capsules of 325 mg / 50 mg / 40 mg / 30 mg capsule+2.4% in 4 weeks
Fair cash price
$45.98
Strengths
1
Makers
2
Updated
Nov 11

Aspirin / butalbital / caffeine / codeine price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
325 mg / 50 mg / 40 mg / 30 mg capsule$1.03$30.85 / 30 capsules+2.4%+6.5%

Brand names of aspirin / butalbital / caffeine / codeine

A brand and its generic share the active ingredient; the generic is almost always far cheaper.

Supply status: shortages & recalls

No shortage reportedChecked Nov 18, 2026
No ongoing recallsNone on record

What did you pay for aspirin / butalbital / caffeine / codeine? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedMay 28, 2026
Version16 of 11
EffectiveMay 27, 2026
Read the label

These highlights do not include all the information needed to use ASCOMP with Codeine safely and effectively. See full prescribing information for ASCOMP with Codeine. ASCOMP with Codeine (butalbital, aspirin, caffeine, and codeine phosphate, USP) capsules, for oral use, CIII Initial U.S. Approval: 1990

This drug has a boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF ASCOMP WITH CODEINE

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF ASCOMP with Codeine

See full prescribing information for complete boxed warning.

ASCOMP with Codeine exposes users to the risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and monitor regularly for these behaviors and conditions. (5.1)

Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or following a dose increase. (5.2)

Accidental ingestion of ASCOMP with Codeine, especially by children, can result in fatal overdose. (5.2)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation. (5.3, 5.9, 7)

Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If prolonged opioid use is required in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. (5.4)

To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for these products. (5.5)

Life-threatening respiratory depression and death have occurred in children who received codeine; most cases followed tonsillectomy and/or adenoidectomy, and many of the children had evidence of being an ultra-rapid metabolizer of codeine due to a CYP2D6 polymorphism. (5.6) ASCOMP with Codeine is contraindicated in children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy (4). Avoid the use of ASCOMP with Codeine in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine.

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. Use of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with ASCOMP with Codeine requires careful consideration of the effects on codeine, and the active metabolite, morphine. (5.7, 5.9, 7)

Addiction, Abuse, and Misuse

Because the use of ASCOMP with Codeine exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1)].

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of ASCOMP with Codeine, especially during initiation or following a dose increase. To reduce the risk of respiratory depression, proper dosing and titration of ASCOMP with Codeine are essential [see Warnings and Precautions (5.2)].

Accidental Ingestion

Accidental ingestion of even one dose of ASCOMP with Codeine, especially by children, can result in a fatal overdose of aspirin, butalbital, caffeine, and codeine phosphate [see Warnings and Precautions (5.2)].

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of ASCOMP with Codeine and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions (5.3), Drug Interactions (7)].

Neonatal Opioid Withdrawal Syndrome

If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery [see Warnings and Precautions (5.4)].

Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)

Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription [see Warnings and Precautions (5.5)].

Ultra-Rapid Metabolism of Codeine and Other Risk Factors for Life-Threatening Respiratory Depression in Children

Life-threatening respiratory depression and death have occurred in children who received codeine. Most of the reported cases occurred following tonsillectomy and/or adenoidectomy, and many of the children had evidence of being an ultra-rapid metabolizer of codeine due to a CYP2D6 polymorphism. [see Warnings and Precautions (5.6)]. ASCOMP with Codeine is contraindicated in children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see Contraindications (4)]. Avoid the use of ASCOMP with Codeine in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine.

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. Use of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with ASCOMP with Codeine requires careful consideration of the effects on codeine, and the active metabolite, morphine [see Warnings and Precautions (5.7, 5.9), Drug Interactions (7)].

Recent major changes (as listed on the label)

Indications and Usage (1) | 04/2023 |

Dosage and Administration (2.1, 2.3) | 04/2023 |

Warnings and Precautions (5.1, 5.2, 5.3, 5.4, 5.7, 5.8, 5.9, 5.12, 5.14) | 04/2023 |

Postmarketing Experience (6.2) | 09/2023 |

OVERDOSAGE (10) | 09/2023 |

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Generic makers
2 approved generic applications on the market

Aspirin / butalbital / caffeine / codeine questions

How much does aspirin / butalbital / caffeine / codeine cost without insurance?

Pharmacies pay about $30.85 for 30 capsules of aspirin / butalbital / caffeine / codeine 325 mg / 50 mg / 40 mg / 30 mg capsule ($1.03 per capsule). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $45.98. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

What is the brand name of aspirin / butalbital / caffeine / codeine?

Aspirin / butalbital / caffeine / codeine is sold as Ascomp. The generic has the same active ingredient and usually costs far less.

Is aspirin / butalbital / caffeine / codeine in shortage?

No shortage is reported for aspirin / butalbital / caffeine / codeine right now. We check the national shortage list every day.

Has aspirin / butalbital / caffeine / codeine been recalled?

No recalls are on record for aspirin / butalbital / caffeine / codeine.

When did the aspirin / butalbital / caffeine / codeine label last change?

The official label was last updated on May 28, 2026 (version 16). See what changed.

Talk about aspirin / butalbital / caffeine / codeine

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.